Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease

Human Molecular Genetics

Volumn 10, Issue 20, 2001, Pages 2313-2318

  Nwosu, Veronica ^a   Carpten, John ^b   Trent, Jeffrey M ^b   Sheridan, Richard ^c  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c DNA Sciences Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; CANCER RISK; CHROMOSOME 16Q; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 20Q; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME XQ; CONTROLLED STUDY; FAMILY; GENE LOCUS; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INHERITANCE; MALE; PENETRANCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0035474113     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/10.20.2313     Document Type: Review

References (78)

1. Cancer statistics, 1999
2. Cancer statistics, 2000
3. Risk factors for prostate cancer
4. Cancer statistics for African Americans, 1996
5. Family history and the risk of prostate cancer
6. Family history facilitates the early diagnosis of prostate carcinoma
7. Hereditary prostate cancer in African-American families
8. Evidence of an X-linked or recessive genetic component to prostate cancer risk
9. The impact of family history on early detection of prostate cancer
10. Mendelian inheritance of familial prostate cancer
11. Segregation analysis of prostate cancer in Sweden: Support for dominant inheritance
12. Evidence for autosomal dominant inheritance of prostate cancer
13. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
14. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus
15. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics
16. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
17. Re: Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
18. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees
19. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
20. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results
21. Linkage analysis of 49 high-risk families does not support a common familial prostate cancer-susceptibility gene at 1q24-25
22. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
23. Linkage analysis of chromosome 1q markers in 136 prostate cancer families
24. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25
25. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe
26. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer
27. No evidence of linkage for chromosome 1q42.2-43 in prostate cancer
28. Evidence for a prostate cancer susceptibility locus on the X chromosome
29. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX
30. Genetic linkage analysis of prostate cancer families to Xq27-28
31. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36
32. Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36
33. Evidence for a prostate cancer-susceptibility locus on chromosome 20
34. Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families
35. Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer
36. A genome screen of multiplex sibships with prostate cancer
37. A candidate prostate cancer susceptibility gene at chromosome 17p
38. Association of HPC2/ELAC2 genotypes and prostate cancer
39. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
40. HPC2 variants and screen-detected prostate cancer
41. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls
42. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4
43. Regression models for linkage heterogeneity applied to familial prostate cancer
44. Confirmation of prostate cancer susceptibility genes using high-risk families
45. A genomic scan of families with prostate cancer identifies multiple Regions of interest
46. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23
47. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer
48. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer
49. Genomewide scan for prostate cancer-aggressiveness loci
50. Molecular cytogenetics of prostate cancer
51. Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus
52. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer
53. Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours
54. Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1, CRC/BPG UK Familial Prostate Cancer Study Collaborators
55. Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer
56. Steroid hormone receptors: Many actors in search of a plot
57. Transcriptional activation and nuclear targeting signals of the human androgen receptor
58. Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors
59. Androgen receptor mutations in prostate cancer
60. Trinucleotide repeat polymorphism in the androgen receptor gene (AR)
61. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups
62. Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression
63. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines
64. Abnormal androgen receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular atrophy)
65. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
66. Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer
67. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
68. Susceptibility to prostate cancer: Interaction between genotypes at the androgen receptor and prostate-specific antigen loci
69. Prostatic steroid 5 α-reductase, an androgen metabolic gene
70. The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer
71. Association of SRD5A2 genotype and pathological characteristics of prostate tumors
72. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
73. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients
74. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4
75. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
76. Polymorphisms in NAT2, CYP2D6, CYP2C19 and GSTP1 and their association with prostate cancer
77. Use of a cDNA microarray to analyse gene expression patterns in human cancer
78. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study